Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M207,602Revenue $M48,851Net Margin (%)14.9Altman Z-Score2.4
Enterprise Value $M223,594EPS $1.1Operating Margin %25.0Piotroski F-Score6
P/E(ttm)27.5Beneish M-Score-2.7Pre-tax Margin (%)18.5Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %3.3Quick Ratio1.2Cash flow > EarningsY
Price/Sales4.35-y EBITDA Growth Rate %6.1Current Ratio1.5Lower Leverage y-yY
Price/Free Cash Flow16.1y-y EBITDA Growth Rate %-23.5ROA % (ttm)4.6Higher Current Ratio y-yN
Dividend Yield %3.4PEG5.0ROE % (ttm)11.3Less Shares Outstanding y-yY
Payout Ratio %101Shares Outstanding M6,184ROIC % (ttm)12.5Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactup Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFEDodge & Cox 2015-12-31 Reduce-1.36%$31.33 - $35.45
($33.17)
$ 33.571%Reduce -95.04%2,243,178
PFEDavid Tepper 2015-12-31 Buy 1.55%$31.33 - $35.45
($33.17)
$ 33.571%New holding2,412,250
PFELeon Cooperman 2015-12-31 Reduce-2.24%$31.33 - $35.45
($33.17)
$ 33.571%Reduce -73.18%1,295,600
PFERuane Cunniff 2015-09-30 Add$30.82 - $36.15
($33.8)
$ 33.57-1%Add 3.05%11,302
PFEDodge & Cox 2015-09-30 Add$30.82 - $36.15
($33.8)
$ 33.57-1%Add 0.07%45,266,436
PFEJohn Keeley 2015-09-30 Reduce$30.82 - $36.15
($33.8)
$ 33.57-1%Reduce -1.78%126,755
PFEKen Fisher 2015-09-30 Add0.01%$30.82 - $36.15
($33.8)
$ 33.57-1%Add 0.35%31,926,879
PFENWQ Managers 2015-09-30 Reduce-0.01%$30.82 - $36.15
($33.8)
$ 33.57-1%Reduce -0.35%4,357,477
PFEJoel Greenblatt 2015-09-30 Add0.01%$30.82 - $36.15
($33.8)
$ 33.57-1%Add 2.27%1,047,861
PFET Rowe Price Equity Income Fund 2015-09-30 Reduce-0.02%$30.82 - $36.15
($33.8)
$ 33.57-1%Reduce -1.08%12,599,315
PFEMario Gabelli 2015-09-30 Reduce-0.02%$30.82 - $36.15
($33.8)
$ 33.57-1%Reduce -10.96%730,005
PFEBarrow, Hanley, Mewhinney & Strauss 2015-09-30 Reduce-0.05%$30.82 - $36.15
($33.8)
$ 33.57-1%Reduce -1.95%54,274,453
PFEDavid Dreman 2015-09-30 Reduce-0.05%$30.82 - $36.15
($33.8)
$ 33.57-1%Reduce -74.15%6,443
PFECharles Brandes 2015-09-30 Reduce-0.08%$30.82 - $36.15
($33.8)
$ 33.57-1%Reduce -3.16%5,863,701
PFEFirst Eagle Investment 2015-09-30 Add0.14%$30.82 - $36.15
($33.8)
$ 33.57-1%Add 41.13%6,090,294
PFEVanguard Health Care Fund 2015-09-30 Reduce-0.46%$30.82 - $36.15
($33.8)
$ 33.57-1%Reduce -35.29%12,550,992
PFEKahn Brothers 2015-09-30 Reduce-0.59%$30.82 - $36.15
($33.8)
$ 33.57-1%Reduce -5.85%1,671,039
PFELeon Cooperman 2015-09-30 Buy 3.06%$30.82 - $36.15
($33.8)
$ 33.57-1%New holding4,830,595
PFEDavid Dreman 2015-06-30 Reduce$33.46 - $35.44
($34.36)
$ 33.57-2%Reduce -1.10%24,926
PFERichard Pzena 2015-06-30 Add$33.46 - $35.44
($34.36)
$ 33.57-2%Add 0.01%2,159,818
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dolsten MikaelPresident R&D 2016-05-04Sell67,588$33.460.33view
LANKLER DOUGLAS MExecutive Vice President 2016-05-04Sell29,700$33.69-0.36view
DAMELIO FRANK AExecutive Vice President 2016-05-03Sell87,079$33.65-0.24view
CANGIALOSI LORETTA VSr. Vice President, Controller 2015-07-30Sell24,704$35.65-5.83view
OLSON LAURIE JExecutive Vice President 2015-06-11Sell26,000$34.39-2.38view
HILL CHARLES HExecutive Vice President 2015-05-29Sell42,870$34.92-3.87view
SUSMAN SALLYExecutive Vice President 2015-03-12Sell46,179$34-1.26view
READ IAN CChairman & CEO 2015-03-05Sell67,500$34.62-3.03view
Dolsten MikaelPresident R&D 2015-03-05Sell58,298$34.46-2.58view
CANGIALOSI LORETTA VSr. Vice President, Controller 2015-02-13Sell104,000$34.73-3.34view

Quarterly/Annual Reports about PFE:

    News about PFE:

    Articles On GuruFocus.com
    UnitedHealth’s Obamacare Changes to Affect Healthcare Sector Apr 27 2016 
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
    Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
    Wilbur Ross Denounces Anti-Business 'Terrible Populist Sentiment' on CNBC Apr 07 2016 
    2 Major Mergers Come to End After Tough Stance From Regulators Apr 07 2016 
    Time To Buy Allergan Apr 06 2016 
    Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
    Jim Simons Purchases Stake in Pfizer Mar 31 2016 
    Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
    Louis Moore Bacon Sells JPMorgan, Pfizer Mar 25 2016 

    More From Other Websites
    Sanofi ready to up offer for drugmaker Medivation, could oust board May 05 2016
    M&A Breakups Have Cost Wall Street $1.2 Billion in 2016 Alone May 05 2016
    Charts are bullish for health care: Technician May 05 2016
    Medivation: And Then There Were Five May 05 2016
    Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings May 05 2016
    Alewife biotech Wave gets validation of its technology in $911M Pfizer deal May 05 2016
    Sanofi Threatens to go Hostile in Medivation Battle May 05 2016
    Pfizer Inc. :PFE-US: Earnings Analysis: Q1, 2016 By the Numbers May 05 2016
    Why Medivation is such an attractive acquisition target May 05 2016
    3 Big Pharma Stocks With Credible Threats to Their Blockbusters May 05 2016
    WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for... May 05 2016
    Panel: Painkiller training should be required for physicians May 04 2016
    Panel: Painkiller training should be required for physicians May 04 2016
    Interest Rises in Medivation Oncology Prospects May 04 2016
    Medivation rises amid possible Pfizer takeover bid May 04 2016
    The Demise of the Market is Greatly Exaggerated May 04 2016
    The Demise of the Market is Greatly Exaggerated May 04 2016
    FDA advisers reconsider training for painkiller prescribers May 04 2016
    Pfizer eyes this San Francisco biotech involved in tight acquisition war May 04 2016
    Will a Third Medivation Suitor Present Itself? May 04 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)